8-K: Tonix Pharmaceuticals Receives Conditional FDA Acceptance for Tonmya Trade Name

Tonix Pharmaceuticals announced that the FDA has conditionally accepted the trade name Tonmya for its TNX-102 SL product candidate intended for the management of fibromyalgia.

Summary

• Tonix Pharmaceuticals has received conditional acceptance from the FDA for the trade name Tonmya for its drug candidate TNX-102 SL, which is intended for the management of fibromyalgia.
• Tonmya is a sublingual tablet formulation of cyclobenzaprine hydrochloride designed for daily use at bedtime to improve sleep quality in fibromyalgia patients.
• The company plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024, following a pre-NDA meeting in the first half of 2024.
• Two positive Phase 3 clinical trials, RELIEF and RESILIENT, have demonstrated Tonmya's effectiveness in reducing daily pain and improving sleep quality, fatigue, and overall fibromyalgia symptoms.
• The RESILIENT study showed a statistically significant reduction in daily pain compared to placebo (p=0.00005), while the RELIEF study also met its primary endpoint with a p-value of 0.010.
• Tonmya is also being developed for other conditions, including fibromyalgia-type Long COVID, alcohol use disorder, and agitation in Alzheimer's disease.
• The company holds patents that are expected to provide U.S. market exclusivity for Tonmya until 2034/2035, with additional pending patents potentially extending exclusivity for other uses until 2041.

Sentiment

Score: 8

Explanation: The document is positive due to the conditional acceptance of the trade name, successful Phase 3 trials, and a clear timeline for NDA submission. The potential for market exclusivity and multiple indications also contribute to the positive sentiment.

Positives

• The conditional acceptance of the Tonmya trade name by the FDA is a positive step towards potential market approval.
• Two positive Phase 3 trials have demonstrated the efficacy of Tonmya in treating fibromyalgia.
• The company has a clear timeline for NDA submission, with a pre-NDA meeting planned for the first half of 2024 and submission in the second half of 2024.
• Tonmya has potential for extended market exclusivity due to existing and pending patents.
• The drug is being developed for multiple indications, including fibromyalgia-type Long COVID, which could expand its market potential.

Negatives

• The acceptance of the trade name is conditional, and final approval is not guaranteed.
• The company is still in the process of seeking FDA approval, which involves regulatory risks and uncertainties.
• There are risks associated with the commercialization of new products, including marketing and competition.

Risks

• There is a risk that the FDA may not approve the NDA for Tonmya.
• The company faces risks related to the timing and progress of clinical development.
• There are risks associated with the company's need for additional financing.
• The company faces uncertainties of patent protection and litigation.
• There are risks related to government or third-party payor reimbursement.
• The company faces substantial competition in the pharmaceutical market.

Future Outlook

Tonix plans to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya for the management of fibromyalgia, following a pre-NDA meeting in the first half of 2024. The company is also developing Tonmya for other indications and has several other drug candidates in its pipeline.

Management Comments

• Seth Lederman, M.D., President and Chief Executive Officer of Tonix Pharmaceuticals, stated that they are very pleased with the FDA's conditional acceptance of Tonmya as the brand name for TNX-102 SL.
• He also expressed excitement about the opportunity to offer the first FDA-approved drug for fibromyalgia patients in more than a decade.

Industry Context

The announcement is significant as it highlights progress in the development of a new treatment option for fibromyalgia, a condition affecting millions of adults in the U.S. The potential approval of Tonmya could provide a new first-line medicine for chronic use in managing this debilitating condition, addressing an unmet need in the market.

Comparison to Industry Standards

• The successful completion of two Phase 3 trials for Tonmya is a positive sign, as many drug candidates fail at this stage.
• The p-values of 0.00005 in the RESILIENT study and 0.010 in the RELIEF study indicate a high level of statistical significance, which is important for regulatory approval.
• The planned NDA submission in the second half of 2024 is a typical timeline for a drug that has completed Phase 3 trials.
• The potential market exclusivity until 2034/2035 is a significant advantage, as it provides a period of protection from generic competition.
• Companies like Eli Lilly (Cymbalta) and Pfizer (Lyrica) have previously marketed drugs for fibromyalgia, but Tonmya's unique formulation and mechanism of action could provide a competitive edge.

Stakeholder Impact

• Shareholders may view this announcement positively due to the progress in drug development and potential for future revenue.
• Fibromyalgia patients may benefit from a new treatment option if Tonmya is approved.
• Employees of Tonix may be positively impacted by the company's progress and potential for growth.

Next Steps

• Tonix plans to have a pre-NDA meeting with the FDA in the first half of 2024.
• The company intends to submit a New Drug Application (NDA) to the FDA in the second half of 2024 for Tonmya for the management of fibromyalgia.
• A Phase 2 study of TNX-1300 is expected to be initiated in the first quarter of 2024.

Key Dates

Keywords

Tonmya, TNX-102 SL, fibromyalgia, FDA, New Drug Application, NDA, clinical trials, pharmaceuticals, cyclobenzaprine, sublingual tablet